

Interim report Q4, 2020.

OCTOBER - DECEMBER 2020

- EBITDA equalled SEK 2,8 million (16,4).
- Operating profit (EBIT) is SEK 0,19 million (10,5)
- Net sales in the period amounted to SEK 35,9 million (48,4) a decrease of 26% on the same period last year
- Profit after tax amounted to SEK -0,691 million (8,6)
- Earnings per share amounted to SEK -0,07 (17 287) per share

FULL YEAR 2020

- EBITDA equalled SEK 16.1 million (13,3).
- Operating profit (EBIT) is SEK 4,5 million (0,1)
- Profit after tax amounted to SEK 1,8 million (0,7)
- Net sales amounted to SEK 137,7 million (127,5) an increase of 8% on the same period last year.
- Earnings per share amounted to SEK 0,24 (1 494) per share

EVENTS DURING THE REPORTING PERIOD

- The fourth quarter has continued to be impacted by the COVID-19 pandemic.
- Magle Chemoswed entered into a binding purchase agreement with PharmaCept GmbH


EVENTS AFTER THE REPORTING PERIOD

- Magle Chemoswed announced the CE Certification of two medical device products.
- Magle Chemoswed completed a directed share issue in January 2021.

KEY FIGURES Q4

	Oct- Dec 2020	Oct - Dec 2019	Full Year 2020	Full Year 2019
Net sales, TSEK	35 914	48 464	137 750	127 569
EBITDA, TSEK	2 865	16 442	16 193	13 393
EBITDA margin, %	8%	34%	12%	11%
Operating profit, TSEK	196	10 585	4 526	136
Net profit/loss for the period, TSEK	-691	8 644	1 819	747
Earnings per share, SEK*	-0,07	17 287	0,24	1 494
Operating cash flow, TSEK	-2 196	-1 118	12 376	-7 085
Operating cash flow per share, SEK	-0,22	-0,11	1,24	-14 170
Equity ratio, %	58%	54%	58%	54%
Equity at period end, TSEK	115 364	113 659	115 364	113 659
Net debt, TSEK	-33 902	-11 821	-33 902	-27 821

*Based on the average numbers of shares. See page 9



CEO comment.

Looking back at 2020, it is increasingly evident that we have entered a significant adjustment period bringing both challenges and opportunities. COVID-19 has caused meaningful and long-lasting changes to markets and business practices that we need to adapt to, not just in the near-term but moving forward into 2021 and beyond. We continue to monitor the situation, as this is a very dynamic and uncertain situation, with the ultimate severity, duration, and impact unknown at this point, including the potential implications on our supply of services, our pipeline development, and our manufacturing continuity and our employees.

Despite the challenges and uncertainty brought about by the global COVID pandemic, I am pleased to report that, for Magle Chemoswed, it was a year of positives amongst the challenges. Our revenues increased year on year by 8%, and we ended 2020 with an EBIDTA of 12% compared with 9% in 2019. Our manufacturing operations for active pharmaceutical ingredients have continued to perform and reach our manufacturing targets. Critical raw materials have proven difficult to secure with price fluctuations causing a further impact on our manufacturing costs. Despite this, we achieved SEK 146,2 million in revenues in 2020 compared with SEK 139,4 million in 2019.

Our contract services performance has seen profitable growth despite the COVID pandemic complications, and we have managed our deliverables to customers well during the year. Our purchase of Adroit Science AB has also significantly contributed to our ability to support customers and generated strong demand and good revenues for services.

We have advanced our pipeline of technology products, even though the challenges of 2020 caused a slight slow-down on progress. With healthy pipeline development of technology products being in focus for our growth strategy moving into the next strate-

gic period of 2021-2024. Since 2018 we have successfully brought three products to CE Mark and approval, an achievement of which we are incredibly proud.

In 2020, we took several actions to improve further our ability to seize future opportunities, including introducing new agile business and project principles to streamline our operations. Of course, our business isn't without its risks and challenges. Being competitive and growing our product portfolio requires that our innovation, investment, and risk-taking are rewarded in the marketplace while doing all that we need to support our value creation goals. And, we need to accomplish all of this while managing through the COVID-19 pandemic. I am confident that the highly motivated, over-performing and excellent team of people within Magle Chemoswed is up to the challenge.

Justin Pierce (CEO) Malmö, February 2021





Manufacturing.

We undertake GMP and ISO manufacturing with a broad range of chemistries at all scales required for Pre-Clinical, Phase I, II, III studies and commercial supply. Our in-house analytical and quality control teams support our manufacturing operations, ensuring the highest quality.

Stable manufacturing demand continued in the last quarter of 2020. Despite headwinds from currency fluctuations revenue contributions from contract manufacturing remained in line with expectations. The sales cost was high due to currency instability and increased cost of critical materials resulting from the COVID pandemic. Three new custom manufacturing agreements strengthened demand and compensated for reduced demand in the first half of the year resulting from COVID. Clinical materials supply was affected by the COVID pandemic with limited orders in the area as a result of a slow down in clinical trials.

OCTOBER - DECEMBER 2020

Sales for the period showed a decrease of 62% compared with the corresponding period last year, a reduction to SEK 6,54 million compared to SEK 17,3 million in 2019. Higher manufacturing

revenues in the 2019 period resulted from an increased contract manufacturing demand for a new active pharmaceutical drug substance for an exclusive customer to support their clinical trials. There was no expectation for repeated income in 2020 from this customer. The supply of the Company's active pharmaceutical ingredients was in line with expectations and forecast for 2020.

FULL YEAR 2020

For full year 2020, manufacturing revenues showed a decrease of 27% compared with the corresponding period last year, to SEK 51,1 million compared to SEK 70,1 million in 2019. The decrease in revenues was influenced by the decision to remove the supply of an active pharmaceutical ingredient in the second quarter of 2019, with an impact of around SEK 10 million. The manufacturing of clinical trial materials for a customer in the last quarter of 2019 contributed to the higher manufacturing revenues in the last quarter of 2019. The fluctuations in clinical supply materials is a normal trend as development projects progress to later stage clinical studies and final product validations. Revenues from the manufacturing of clinical supply materials is expected to fluctuate year to year.



Services.

We have a highly experienced and flexible team dedicated to our service offerings. We offer a full range of development services covering the development chain for pharmaceuticals and medical devices. With over 70 years of combined experience, we have a rich history in successfully providing development services.


Our integrated group of scientists provides a seamless transition for API and drug substances from the program's initial discovery stages to more in-depth process development. Our teams have extensive experience in route or step rebuild, process optimization and impurities assessment and synthesis. Provision of services in the analysis and process development of drug and medical device candidates on a contract services basis provides on-going revenues. In 2020 growth has been achieved by introducing the increased integrated services from the acquisition of Adroit Science AB. Demand for development services has been constant in the quarter. We have on-boarded two new projects in the period. The need for development and analytical services remains steady with our business development team working hard to generate future opportunities.

OCTOBER - DECEMBER 2020

Demand for development and support services remained high in the period both in new and existing projects. Sales for the period showed an increase of 239% compared with the corresponding period last year, increasing to SEK 23,3 million compared to SEK 6,8 million in 2019. The increase in revenues is driven by the addition of the Solid State business arising from the acquisition of Adroit AB and from the increased number of projects in development been supported with CDMO services.

FULL YEAR 2020

Sales for the period showed an increase of 97% compared with the corresponding period last year, an increase of SEK 16,4 million to SEK 55,6 million compared to SEK 27,5 million in 2019. Our portfolio of contract development projects is a mix of early-stage exploratory clients and late-stage pre-validation clients.



Technology product and royalty.

As an integrated company, we have extensive capabilities across the value chain, from the discovery, development and manufacture of medicines and medical devices that rely on our patented and trade secret protected technology platform.


EmboCept™S is an embolic agent made up of microspheres in a solution used to treat inoperable liver and lung tumours. Vascular embolization is when an embolic agent is injected into the blood vessel to close the blood vessels and stop the blood flow to a targeted tumour area. The product is marketed across Europe, Israel and Singapore. In 2021 the company plans to increase market share by registering the product into new territories.

SmartPan™ is a first in class medical device product designed to detect pancreatic fluid leakage during surgical procedures. Pancreatic fluid detection during surgical procedures provides an assurance of a minimised risk to patients from surgical complications arising from pancreatic fluid leakage. The product was

approved for sale in Europe (CE marked) in January 2021 and will be rolled out in collaboration with Heidelberg University Hospital before entering into commercial sales in Europe.

SmartGel is a non-allergenic hydrogel based on the company's microsphere technology. The gel delivers moisture to the wound, whilst maintaining enough absorption capacity for exudate, debris and bacteria. The product received approval for marketing in Europe in January 2021 and is in the pre-marketing phase.

Royalties are received quarterly from Becton Dickinson for an out-license agreement for rights to the company technology. In the period of October-December 2020 the royalty received was SEK 6,0 million (24,2). Royalty for January - December 2020 was SEK 30,9 million (29,2).





Near-term pipeline.

We have a dedicated and highly experienced research and development team that is supported through the integration of the services we offer as a company. Our development is expedited due to our ability to develop in parallel with analytic, formulation and manufacturing expertise.

1. EmboCept™M is an embolic agent made up of microspheres in solution used for the treatment of benign prostatic hyperplasia also called prostate enlargement, which is a noncancerous increase in size of the prostate gland. The product is designed for prostatic artery embolization which is a minimally invasive treatment that helps improve lower urinary tract symptoms caused by a benign prostatic hyperplasia. The product is in late stage validation and is being prepared for regulatory filing in 2021.

2. EmboCept™L is an embolic agent made up of microspheres in solution used for the treatment of uterine fibroids which are noncancerous growths of the uterus that often appear during

childbearing years. Uterine fibroid embolization is a non surgical way of treating fibroids by blocking off the arteries that feed the fibroids, the uterine arteries, and making the fibroids shrink. The product is in late stage design verification and is being prepared for validation in 2021.

3. SmartBone is a combination formulation of microspheres and active ingredients for use in hard tissue procedures where patients need remodeling to the patient's own bone and to ensure that bone growth is supported and sustained through a microsphere matrix that is full bio-compatible and bio-degradable. The product is in the conceptualization stage and will be further developed through the design and development phase in 2021.

The company's near-term pipeline builds on the EmboCept brand than can be expedited to the market. The pipeline also includes candidates for new markets.

Candidate	Phase 1 Ideation	Phase 2 Conceptualisation	Phase 3 Design & Development	Phase 4 Design Verification	Phase 5 Design Validation
EmboCept M Embolisation microsphere for Benign Prostatic Hyperplasia					
EmboCept L Embolisation microsphere for Uterine Fibroids					
SmartBone Bone repair matrix at implant sites					



Financial overview Q4, 2020.

net sales

Net sales in the period amounted to SEK 35,9 million (48,4) a period decrease of 26%. The API revenues decreased by 67% to SEK 6,3 million (19,1). Sales in CDMO services increased by 239% to SEK 23,3 (6,8). Medical device sales were at TSEK 229 (581). The technology royalties for the period were SEK 6,0 million (24,2).

raw materials and consumables

Raw materials and consumables amounted to SEK 7,8 million (5,2), which resulted in a gross margin of 72% (89).

other external expenses

Other external expenses amounted to SEK 9,0 million (12,8). External costs include costs associated with the listing of the company.

personnel costs

Staff costs totaled to SEK 16,5 (15,7). Personnel costs increased by 5% due to the collective agreement salary increases.

other operating income, expenses

Other operating income and expenses consisted mainly of exchange gains and losses on operating assets and liabilities and sale of media to neighboring business. Other operating income amounted to SEK 0,492 (3,9) and other operating expenses amounted to SEK 0 million (2,7) for the quarter.

operating result

Operating profit amounted to SEK 0,196 million (10,5).

net financial items

Net financial items amounted to SEK -1,0 million (1,5).

profit/loss for period

For the reasons explained above, the profit/loss for the fourth quarter amounted to SEK -691 million (8,6), which corresponds to earnings per share of SEK -0,07.

Financial Position	Oct.-Dec. 2020	Oct.-Dec. 2019
TSEK		
Cash & cash equivalents	6 122	-1 767
Interest-bearing debt	40 024	67 749
Net debt	-33 902	-27 821
Equity	115 364	35 455

Cashflow	Oct.-Dec. 2020	Oct.-Dec. 2019	Full Year 2020	Full Year 2019
TSEK				
Operations	-2 196	-1 118	12 376	-7 085
Investing activities	789	-8 745	-6 593	-66 600
Financing activities	-7 564	10 083	-3 272	74 738

Condensed consolidated Magle Chemoswed Group income statement

	Oct.-Dec. 2020	Oct.-Dec 2019	Full Year 2020	Full Year 2019
TSEK				
Revenues				
Net sales	35 914	48 464	137 750	127 569
Work performed by the company for its own use and capitalized	0	601	0	4 214
Other revenues	492	3 993	8 501	7 706
Total	36 406	53 058	146 252	139 489

Raw materials and consumables	-7 896	-5 272	-30 395	-27 576
Other external expenses	-9 068	-12 859	-40 801	-38 416
Personnel costs	-16 577	-15 726	-58 859	-57 345
Depreciation and amortization	-2 668	-5 857	-11 667	-13 257
Other operating expenses	0	-2 759	-3	-2 759
Total operating expenses	-36 210	-42 473	-141 726	-139 353

Operating profit/loss	196	10 585	4 526	136
------------------------------	------------	---------------	--------------	------------

Profit/loss from financial items				
Financial income	0	1 207	706	1 473
Financial expenses	-1 005	388	-2 798	-546

Profit before tax	-809	12 180	2 434	1 063
--------------------------	-------------	---------------	--------------	--------------

Taxes for the period	118	-3 536	-614	-316
-----------------------------	------------	---------------	-------------	-------------

Net profit/loss for the period	-691	8 644	1 819	747
---------------------------------------	-------------	--------------	--------------	------------

Condensed consolidated Magle Chemoswed Group statement of comprehensive income

	Oct.-Dec. 2020	Oct.-Dec 2019	Full Year 2020	Full Year 2019
TSEK				
Profit/loss for the period	-691	8 644	1 819	747
Other comprehensive income	0	0	0	0
Items to be reclassified to profit or loss in subsequent periods	0	0	0	0
Exchange differences	0	72		72
Total comprehensive income for the period	-691	8 716	1 819	819

Earnings per share

	Oct.-Dec. 2020	Oct.-Dec. 2019	Full Year 2020	Full Year 2019
Equity holders of the parent				
Earnings per share before dilution	-0,07	17 287	0,24	1 494
Earnings per share after dilution*	-0,07	17 287	0,24	1 494
Profit/loss for the period	-691	8 644	1 819	747
Average number of shares, thousands				
Average number of shares before dilution	10 000	0,5	7 617	0,5
Average number of shares after dilution	10 000	0,5	7 617	0,5

*A share split was carried out on the 27th of March 2020

Condensed consolidated Magle Chemoswed group balance sheet

	December 2020	December 2019
TSEK		
ASSETS		
Intangible assets	28 966	27 998
Tangible assets	104 029	102 090
Deferred tax asset	2	1 437
Other non-current assets	55	3 277
Total non-current assets	133 052	134 802
Inventories	18 348	27 243
Trade receivables	26 271	18 424
Other operating receivables	14 271	28 515
Cash and cash equivalents	6 122	3 294
Total current assets	65 012	77 476
TOTAL ASSETS	198 065	212 278
EQUITY AND LIABILITIES		
Equity attributable to equity holders of the parent	116 121	113 659
Liabilities to credit institutions	28 938	4 750
Leasing debt	3 159	3 057
Deferred tax liability	2 087	4 992
Total non-current liabilities	34 183	12 799
Liabilities to credit institutions	11 086	10 365
Leasing debt	1 637	800
Trade payables	12 365	17 190
Other operating liabilities	22 671	57 465
Total current liabilities	47 760	85 820
TOTAL EQUITY AND LIABILITIES	198 065	212 278

Consolidated Magle Chemoswed Group statement of changes in equity

	Share capital	Other paid in capital	Reserves	Retained earnings incl. P/L for year	Total equity
TSEK					
As at 1 January 2019	50	36 834	-72	13 860	50 672
Profit/loss as at 31 March 2018					0
Other comprehensive income as December 2019	0	62 093	72	822	62 987
Equity as at 31 December 2019	50	98 927	0	14 682	113 659
As at 1 January 2020	50	98 927	0	14 682	113 659
Profit/loss as at 31 December 2020				1 819	1 819
Other comprehensive income as at 31 December 2020	0	646	0	0	646
Warrants	450	861	0	-2 071	-760
other comprehensive income as 31st of December	500	1 507	0	14 430	115 364

Consolidated Magle Chemoswed Group statement of cashflows

	Oct-Dec 2020	Oct-Dec 2019	Full Year 2020	Full Year 2019
TSEK				
Operating profit/loss	196	10 585	4 526	136
Non-cash adjustments:				
- Sale of subsidiary company	0	0	0	290
- depreciation	2 668	5 857	11 667	13 257
Interests received	0	1 207	706	266
Interests paid	-1 005	388	-2 798	-274
Income tax paid	118	2 341	100	931
Net cash flows from operating activities before changes in working capital	1 977	20 377	14 202	14 606
Changes in working capital	-3 416	-21 495	-1 069	-21 691
Net cash flow from operating activities	-1 439	-1 118	13 133	-7 085
Acquisition of subsidiary company	0		0	-11 733
Investments in intangible assets	-1 344	-396	-1 925	-3 160
Investments in tangible assets	1 376	-8 349	-5 425	-51 707
Net cash flows from investing activities	32	-8 745	-7 350	-66 600
Loans raised	-8 854	10 010	18 732	14 948
Repayments of bank loan	0	-1 021	-5 940	-1 917
Repayment of shareholder loan	0	0	-16 000	0
Repayments of leasing	1 290	1 094	-695	-386
Shareholders contribution	0	0	631	62 093
Net cash flow from financing activities	-7 564	10 083	-3 272	74 738
Net cash flow	-8 971	220	2 511	1 053
Cash and cash equivalents at beginning of period	15 092	3 074	3 610	2 241
Cash and cash equivalents at end of period	6 121	3 294	6 121	3 294

Parent company income statement

	Oct.-Dec. 2020	Oct.-Dec. 2019	Full Year 2020	Full Year 2019
TSEK				
Net sales	0	33 236	-0	45 220
Intercompany revenue	1 049		1 186	
Other revenues	-	-6 026	1 173	233
Total	1 049	27 210	2 359	45 453
Other external expenses	-493	-937	-3 924	-2 586
Personnel costs	-35	-1 896	-1 203	-6 901
Depreciation and amortization	-	122	-	
Other operating expenses	-	-82	-	-82
Operating profit/loss	521	24 417	-2 768	35 884
Net financial items	-368	609	-375	-168
Profit loss after financial items	153	25 026	-3 143	35 716
Appropriations	-	-35 650		-35 650
Group contribution	3 033		3 033	
Taxes for the period	-705	2 347	-0	-27
Net profit/loss for the period	2 480	-8 277	-110	39

Parent company balance sheet

	December 2020	December 2019
TSEK		
ASSETS		
Non-current assets	44 647	44 627
Other receivables	45 566	127 423
Prepaid expenses	33	11 983
Cash and cash equivalents	-4 701	2
TOTAL ASSETS	85 546	184 035
EQUITY AND LIABILITIES		
Equity		
Restricted equity	500	50
Unrestricted equity	71 366	71 283
Total equity	71 866	71 333
Current liabilities	13 680	112 702
TOTAL EQUITY AND LIABILITIES	85 546	184 035

note 1

GENERAL INFORMATION, ACCOUNTING PRINCIPLES

This interim report was prepared in accordance with IAS 34 Interim Financial Reporting and the Swedish Annual Accounts Act. The parent company's reporting has been prepared in accordance with RFR 2, Reporting for Legal Entities, and the Swedish Annual Accounts Act. Accounting principles have been applied as reported for the Annual Report per 31 December 2019. New or amended standards or interpretations of standards effective as of 31 December 2020 have not had any significant impact on Magle Chemoswed's financial statements.

note 2

SIGNIFICANT RISKS AND UNCERTAINTIES

The Group is exposed to various financial risks. The business is impacted by many factors that could affect the Group's result and financial position. It is Magle Chemoswed's strategy to continuously identify and manage risks. Financial risk management is described in the Prospectus.

note 3

TRANSACTIONS WITH RELATED PARTIES

The financial reports include costs related to the following transactions between Magle Chemoswed and related parties.

Related Party	Service	Full Year 2020	Full Year 2019
Crowberry Group AB (Hedda Lidgard, board member)	Consultancy	630 (TSEK)	0

note 4

FINANCIAL ASSETS AND LIABILITIES

Fair values of current financial assets and liabilities are assessed agree with values accounted for.

note 5

SEGMENT INFORMATION

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The chief operating decision maker is the function responsible for allocating resources and assessing the performance of the operating segments. In the Magle Chemoswed Group, the CEO has been identified as the chief operating decision maker who evaluates the Group's financial position and performance and makes strategic decisions. The CEO analyzes and monitors the business performance based on the Group as a whole. The assessment is thus that the Group's operations consist of one operating segment.

By nature of income	Oct.- Dec. 2020	Oct.- Dec. 2019	Full Year 2020	Full Year 2019
TSEK				
API revenues (Manufacturing page 3)	6 317	16 768	47 804	69 520
Services revenues (Services page 4)	23 313	6 873	55 674	28 195
Medical device (Manufacturing page 3)	229	581	3 316	581
License revenues (Technology Product and Royalty page 5)	6 056	24 242	30 957	29 273
Total	35 915	48 464	137 750	127 569

By country	Oct.- Dec. 2020	Oct.- Dec. 2019	Full Year 2020	Full Year 2019
TSEK				
Sweden	10 361	1 670	18 718	4 114
Europe excluding Sweden	7 877	8 106	44 725	34 863
Other territories	17 676	38 688	74 308	88 592
Total	35 915	48 464	137 750	127 569

By company	Oct.- Dec. 2020	Oct.- Dec. 2019	Full Year 2020	Full Year 2019
TSEK				
Magle Chemoswed AB	34 589	22 917	133 262	96 991
Magle Chemoswed Holding AB	0	24 242	0	29 273
Adroit Science AB*	1 325	1 305	4 488	1 305
Total	35 914	48 464	137 750	127 569

*Adroit Science revenues have been largely incorporated into the Magle Chemoswed AB operational business.



Definitions.

Magle Chemoswed uses Alternative Performance Measures (APM) to enhance understandability of the information in the financial reports, both for external analysis and comparison and internal performance assessment.

Alternative Performance Measures are key figures not defined in financial reports prepared according to IFRS. The following key figures are used:

sales growth

The difference in net sales between two periods in relation to net sales for the earlier period. Shows the operations sales performance.

interest bearing debt

Borrowings from banks, financial institutions and lease liabilities, short and long term. Shows the debt level of the group and forms the base for interest expenses.

net debt

Interest bearing debt minus cash and cash equivalents. Shows the group's net debt and is used to measure the leverage level of the group and future funding needs.

Sales Growth	Oct-Dec 2020	Oct-Dec 2019	Full Year 2020	Full Year 2019
Net sales, TSEK	35 914	48 464	137 750	127 569
Sales growth, %	-26%	65%	8%	20%
Gross profit, TSEK	28 018	43 192	107 355	86 263
Gross margin, %	78%	89%	78%	68%

Indicators	Oct-Dec 2020	Oct-Dec 2019	Full Year 2020	Full Year 2019
Non-current borrowings, TSEK	28 938	4875	28 938	4 750
Current borrowings, TSEK	11 086	1 250	11 086	10 365
Interest bearing debt, TSEK	40 024	68 228	40 024	31 115
Cash and cash equivalents, TSEK	6 122	3 610	6 122	3 294
Net debt, TSEK	-33 902	-64 618	-33 902	-27 821

note 6

NUMBER OF SHARES

Ordinary Shares	Number of shares	Potential shares
31 December 2019	500	
30 June 2020	10 000 000	300 000

Share split was made on 27th of March 2020.

note 7

WARRANTS

At period end, there is one warrant program. The warrant program was executed in 2020. Warrants give the holder the right to acquire 1 ordinary share.

Warrant program	Number of options	Equals number of shares
Balance January 1, 2020	0	
Balance March 30, 2020	0	
Balance December, 31, 2020	225 000	225 000

DECLARATION OF THE BOARD OF DIRECTORS AND THE CEO

The undersigned Board members assure that this Interim report provides a true and fair view of the development of the Group's and Parent Company's operations, position and performance as well as describing material risks and uncertainties faced by the companies being part of the Group. This interim report has not been reviewed by the Company's auditors.



Hans Henrik Lidgard (Chair)



Sven Christer Nilsson



Mats Pettersson



Malin Malmsjö



Hedda Lidgard



Joel Eklund



Justin Pierce (CEO)



Ingela Fritzon



Simon Mårtensson

Malmö February 25, 2021

This information is information that Magle Chemoswed Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above 2020-07-14, at. 07.00.

FORTHCOMING DISCLOSURES OF INFORMATION

FINANCIAL CALENDAR

DATE

ANNUAL REPORT 2020

14TH APRIL, 2021

CONTACT INFORMATION

Justin Pierce, CEO, phone +46 (0)70 593 58 21, justin.pierce@maglechemoswed.com

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.